NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · MID CAP
Innate Pharma SA IPHA
9 fiscal years on record · EUR · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
€9.0M
▼ 55.2% vs FY2024
EPS · FY25
€-0.55
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-546.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
EUR 9.0M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 546 cents on every revenue dollar this year.
Per share
EUR -0.55
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-599.8%
Net margin-546.1%
Return on assets-56.6%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−33.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−46.2%
−33.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
EUR 62.7M
total assets, end of FY2025
Total assetsEUR 62.7M
CashEUR 28.1M
Current ratio1.27×
History
9 fiscal years
Every figure from documents filed with the SEC · EUR
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue €B
0.0
0.0
0.1
0.1
0.0
0.1
0.1
0.1
0.0
Operating income €B
−0.1
−0.1
−0.0
−0.1
−0.0
0.0
0.0
0.0
−0.0
EBITDA €B
−0.1
−0.0
−0.0
−0.1
−0.0
0.0
0.0
0.0
−0.0
Income tax €B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
Net income €B
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.0
0.0
−0.0
EPS, diluted €
−0.55
−0.61
−0.09
−0.73
−0.66
−0.81
−0.31
0.05
−0.89
Dividend / sh €
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
Shares out B
·
·
·
0.08
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
27 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed